About Enhancer

Enhancer ID: E_01_0438
Species: human
Position : chr4:186066731-186068731
Biosample name:
Experiment class : High+Lowthroughput
Enhancer type: Enhancer
Disease: Inflammation, cancer
Pubmed ID:  29853604
Enhancer experiment: Western blot,Image flow analysis,Immunofluorescence,Phospho-CREB activation,RT-PCR,ELISA,chemotaxis assays,
Enhancer experiment description: This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies.

About Target gene

Target gene : TLR3,CCL22,CXCL12
Strong evidence: qRT-PCR,qPCR,ChIP,3C
Less strong evidence: RNA-Seq
Target gene experiment description: This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies.

About TF

TF name : TRAF3IRF3CXCL10IL10
TF experiment: Western blot,Image flow analysis,Immunofluorescence,Phospho-CREB activation,RT-PCR,ELISA,chemotaxis assays,
TF experiment description: This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies. ;This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies.

About Function

Enhancer function : This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies.
Enhancer function experiment: Immunohistochemical staining
Enhancer function
experiment description:		 This study characterizes two different poly-I:C-induced signaling pathways in their induction of immunostimulatory and suppressive factors and suggests improved ways to reprogram the TME to enhance the antitumor efficacy of immunotherapies.

About SNP

SNP ID: --

Upstream Pathway Annotation of TF

GeneName Pathway Name Source Gene Number
TRAF3 Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon reactome 18
TRAF3 CD40/CD40L signaling pid 36
TRAF3 Negative regulators of RIG-I/MDA5 signaling reactome 34
TRAF3 RANKL netpath 84
TRAF3 TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway reactome 17
TRAF3 TNFalpha netpath 274
TRAF3 TNFR2 non-canonical NF-kB pathway reactome 63
TRAF3 TRAF3-dependent IRF activation pathway reactome 14
TRAF3 TWEAK netpath 35
TRAF3 Toll-like receptor signaling pathway kegg 100
TRAF3 RIG-I-like receptor signaling pathway kegg 71
TRAF3 Hepatitis C kegg 134
TRAF3 Pathways in cancer kegg 321
TRAF3 Small cell lung cancer kegg 83
TRAF3 Hs_Apoptosis_Modulation_and_Signaling_WP1772_91293 wikipathways 71
TRAF3 Hs_Regulation_of_toll-like_receptor_signaling_pathway_WP1449_81172 wikipathways 47
TRAF3 Hs_Toll-like_Receptor_Signaling_Pathway_WP75_83867 wikipathways 17
TRAF3 Hs_RIG-I-like_Receptor_Signaling_WP3865_88186 wikipathways 19
TRAF3 Hs_Toll-like_Receptor_Signaling_WP3858_89945 wikipathways 7
IRF3 Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon reactome 18
IRF3 Factors involved in megakaryocyte development and platelet production reactome 111
IRF3 Interferon alpha/beta signaling reactome 67
IRF3 Interferon gamma signaling reactome 88
IRF3 IRF3-mediated induction of type I IFN reactome 13
IRF3 IRF3 mediated activation of type 1 IFN reactome 6
IRF3 ISG15 antiviral mechanism reactome 73
IRF3 LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production reactome 5
IRF3 Negative regulators of RIG-I/MDA5 signaling reactome 34
IRF3 Regulation of innate immune responses to cytosolic DNA reactome 14
IRF3 Toll receptor signaling pathway panther 44
IRF3 TRAF3-dependent IRF activation pathway reactome 14
IRF3 TRAF6 mediated IRF7 activation reactome 33
IRF3 Toll-like receptor signaling pathway kegg 100
IRF3 RIG-I-like receptor signaling pathway kegg 71
IRF3 Cytosolic DNA-sensing pathway kegg 56
IRF3 Hepatitis C kegg 134
IRF3 Hs_p38_MAPK_Signaling_Pathway_WP400_72084 wikipathways 28
IRF3 Hs_Complement_and_Coagulation_Cascades_WP558_90196 wikipathways 21
IRF3 Hs_RIG-I-like_Receptor_Signaling_WP3865_88186 wikipathways 19
IRF3 Hs_TLR4_Signaling_and_Tolerance_WP3851_90114 wikipathways 8
CXCL10 Chemokine receptors bind chemokines reactome 57
CXCL10 CXCR3-mediated signaling events pid 38
CXCL10 G alpha (i) signalling events reactome 241
CXCL10 Inflammation mediated by chemokine and cytokine signaling pathway panther 189
CXCL10 Cytokine-cytokine receptor interaction kegg 213
CXCL10 Chemokine signaling pathway kegg 187
CXCL10 Toll-like receptor signaling pathway kegg 100
CXCL10 RIG-I-like receptor signaling pathway kegg 71
CXCL10 Cytosolic DNA-sensing pathway kegg 56
IL10 AP-1 transcription factor network pid 71
IL10 Heterotrimeric GPCR signaling pathway (through G alpha i and pertussis toxin) ( GPCR signaling (pertussis toxin) ) inoh 228
IL10 Heterotrimeric GPCR signaling pathway (through G alpha q, PLC beta and ERK cascade) ( GPCR signaling (G alpha q) ) inoh 239
IL10 Heterotrimeric GPCR signaling pathway (through G alpha s ACs Epac BRaf and ERKcascade) ( GPCR signaling (G alpha s, Epac and ERK) ) inoh 237
IL10 Heterotrimeric GPCR signaling pathway (through_G alpha s_ACs_PKA_BRaf_and_ERKcascade)(canonical) ( GPCR signaling (G alpha s, PKA and ERK) ) inoh 227
IL10 Heterotrimeric GTP-binding protein coupled receptor signaling pathway (through G alpha i, adenylate cyclase and cAMP) ( GPCR signaling (G alpha i) ) inoh 228
IL10 Heterotrimeric GTP-binding protein coupled receptor signaling pathway (through_G_alpha_s,_cholera_toxin,_adenylate_cyclase_and_cAMP) ( GPCR signaling (cholera toxin) ) inoh 227
IL10 IL-10 signaling pathway(JAK1 TYK2 STAT3) ( IL-10 signaling(JAK1 TYK2 STAT3) ) inoh 6
IL10 IL4-mediated signaling events pid 66
IL10 Interleukin signaling pathway panther 86
IL10 JAK-STAT pathway and regulation pathway ( JAK-STAT pathway and regulation pathway Diagram ) inoh 97
IL10 Regulation of nuclear SMAD2/3 signaling pid 82
IL10 Cytokine-cytokine receptor interaction kegg 213
IL10 Jak-STAT signaling pathway kegg 149
IL10 T cell receptor signaling pathway kegg 105
IL10 Intestinal immune network for IgA production kegg 48
IL10 Leishmaniasis kegg 71
IL10 Chagas disease kegg 103
IL10 Malaria kegg 50
IL10 Toxoplasmosis kegg 131
IL10 Amoebiasis kegg 103
IL10 Staphylococcus aureus infection kegg 54
IL10 Asthma kegg 29
IL10 Autoimmune thyroid disease kegg 52
IL10 Systemic lupus erythematosus kegg 136
IL10 Allograft rejection kegg 37
IL10 Hs_Osteoblast_Signaling_WP322_90527 wikipathways 10
IL10 Hs_Signaling_of_Hepatocyte_Growth_Factor_Receptor_WP313_79946 wikipathways 15
IL10 Hs_Hypertrophy_Model_WP516_88898 wikipathways 17
IL10 Hs_Regulation_of_Actin_Cytoskeleton_WP51_79977 wikipathways 36

Enhancer associated network

The number on yellow line represents the distance between enhancer and target gene

Expression of target genes for the enhancer

Enhancer associated SNPs